Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22047555 | 0.84 | PTGS1 (0.31) | PTGS1 | |
| SCHEMBL18822482 | 0.80 | — | — | |
| SCHEMBL22380075 | 0.80 | TDP1 (0.35) | — | |
| SCHEMBL346616 | 0.77 | PTGS1 (0.71) | PTGS1AKR1C3 | |
| SCHEMBL18556334 | 0.77 | — | — | |
| SCHEMBL20362677 | 0.77 | — | — | |
| SCHEMBL28176299 | 0.75 | PTGS1 (0.68) | PTGS1AKR1C3 | |
| SCHEMBL23544310 | 0.73 | — | — | |
| SCHEMBL292979 | 0.73 | — | — | |
| SCHEMBL292980 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230069813-A9 | Multiple Unit Dosage Form Having A Therapeutic Agent In Combination With A Nutritional Supplement | BONAFIDE HEALTH, LLC | 2023-03-02 | — | — | US | disclosed |
| US-RE46605-E1 | Fatty acid niacin conjugates and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-7989430-B2 | Antibacterial agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080293666-A1 | Antibacterial Agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230069813-A9 | Multiple Unit Dosage Form Having A Therapeutic Agent In Combination With A Nutritional Supplement | SLC5A6, SLC19A1, SLC25A20 | PTGS1 2449/4885AKR1C3 2258/4885 |
| US-20080293666-A1 | Antibacterial Agents | MRPL21, ABCB7, MSR1 | PTGS1 941/4885AKR1C3 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.